DCF化疗方案与培美曲塞联合治疗胃癌的临床研究

Clinical research of DCF chemotherapy regimen combined with pemetrexed in the treatment of gastric cancer

[目的]探究DCF化疗方案与培美曲塞联合治疗胃癌的临床效果及对肿瘤标志物和肝肾功能的影响。[方法]将收治的100例胃癌患者随机分为研究组和对照组,对照组给予DCF化疗方案治疗,研究组给予DCF化疗方案与培美曲塞联合治疗,检测2组患者治疗后临床治疗效果及治疗前后肿瘤标志物、肝肾功能指标变化。[结果]研究组治疗后显效率、总有效率均明显高于对照组(P<0.05)。与治疗前相比,2组治疗后肿瘤标志物癌胚抗原(CEA)、CA199和CA724显著降低,肝肾功能指标谷丙转氨酶(ALT)、谷草转氨酶(AST)、血尿素氮(BUN)、血清肌酐(Cre)均显著升高,治疗前后比较差异有统计学意义(P<0.05)。治疗后研究组胃癌患者肿瘤标志物(CEA、CA199和CA724)显著低于治疗后对照组,2组比较差异有统计学意义(P<0.05),而治疗后2组肝肾功能指标(AST、ALT、BUN、Cre)变化不明显,比较差异无统计学意义(P>0.05)。[结论]DCF化疗方案与培美曲塞联合治疗能够提高胃癌患者临床治疗效果、降低肿瘤标志物水平,同时具有较低不良反应。

[Objective]To observe the treatment effect, tumor markers and liver and kidney function of DCF chemotherapy regimen combined with pemetrexed in the treatment of gastric cancer to offer reference for gastric cancer treatment. [Methods]A total of 100 patients with gastric cancer were selected and ran- domly divided into two groups（the research group and the control group）. The control group patients were treated with DCF chemotherapy regimen. The research group patients were treated with DCF chemothera- py regimen combined with pemetrexed. Treatment effect of two groups was observed. Before and after treatment, the changes of tumor markers, liver and renal function indexes were analyzed. The related mech- anism of combined therapy was analyzed. [Results]After treatment, significant efficiency,and total efficien- cy in the research group were significantly higher than those in the control group（P^0.05）. Compared with that before treatment, the tumor markers carcino-embryonie antigen（CEA）, CA199 and CA724 were significantly decreased,while liver and kidney function indexes Alanine aminotransferase（ALT）, aspartate transaminase（AST） ,blood urea nitrogen（BUN）,and creatinine（Cre）were significantly increased in the two groups （P（0.05）. After treatment, the tumor markers （CEA, CA199 and CA724） in the study group were significantly lower than those in the control group（P（0.05）. After treatment,the changes of liver and kid- ney function indicators（AST,ALT,BUN,and Cre）in two groups had not significant difference（P）0.05）. [Conclusion]The combination of DCF chemotherapy regimen and pemetrexed can improve the clinical treat- ment effect, reduce the level of tumor markers, and have lower side effects.